Medical device maker Medtronic PLC NYSE: MDT is a Dividend Aristocrat in the medical and healthcare sectors. The medical device maker has raised its dividend payout for 46 consecutive years through...

Medtronic is the world's largest medical device company, and it has a 46-year streak of consecutive annual dividend raises. Cigarette sales are steadily declining, but Altria Group's bottom line ke...

Medtronic MDT (NYSE: MDT) recently reported its Q3 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating the street estimates. The company reported revenue of $8.1 billion ...

Thesis & Performance: Previous analysis suggested a fair price of $137.6; Q3 2024 earnings beat estimates, affirming my "strong buy" recommendation. Financial Overview: Q3 2024 earnings reported re...

Medtronic's choice to retain its PMRI Business is mainly driven by the improved performance of its Patient Monitoring segment in recent times, is a result of a comprehensive evaluation of its portf...

Medtronic's business showed signs of promise in Q3, with revenue growth of around 5%. The company is exiting its ventilator product line, which should improve profitability.

Medtronic beat revenue and earnings estimates for its fiscal third quarter. Growth was broad-based across product portfolios.

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Shares of Medtronic PLC (MDT) gained Tuesday after the medical technology firm posted better-than-expected results and raised its guidance on increased demand for its heart and diabetes devices.

Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, Medtronic's business in China, and how Martha is thinking about the company's portfolio.

Medtronic (MDT) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.30 per share a year ago.

Medtronic reported adjusted per-share earnings of $1.30, beating Wall Street's call for $1.26, according to FactSet.

Medtronic's revenue soars 88%, leading healthcare innovation, while Non-GAAP EPS up 40%, showcasing steady growth. Medtronic has decent growth opportunities and limited risks. With Medtronic's P/E ...

Medtronic has a history of dividend increases and is well-positioned for long-term growth in the healthcare industry. The company's financial performance has been solid, with stable margins and con...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Medtronic (MDT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for th...